Autoinflammatory & rare systemic diseases
The clinical outcomes and healthcare resource utilization in IgG4-related disease: a claims-based analysis of commercially insured adults in the United States
Authors' conclusion
Patients with IgG4-RD are disproportionately affected by adverse outcomes, some of which may be preventable or modifiable with vigilant clinician monitoring.
Study context
- Population
- Commercially insured adults in a US managed care organization claims database
- Participants
- 524 vs 5,240
- Exposure
- Incident igG4-related disease (IgG4-RD) cases vs matched general population comparators
- Casesn = 524
- Comparatorsn = 5,240reference
- Outcome
- Frequency of 21 expert-defined clinical outcomes associated with IgG4-RD or its treatment, and healthcare-associated visits and costs
- Follow-up
- 12 months before and 36 months after the index date
Methodological detailsclaims-based, matched by age, sex, race/ethnicity and index date
- Claims-based
- Matched by age, sex, race/ethnicity and index date
Main finding
As reported in the abstract
Clinical outcomes, prevalence difference cases vs comparators · follow-up
- Clinical outcomes, prevalence difference cases vs comparators
- prevalence difference (gastroesophageal reflux disease) +31.2%; P < 0.001
- Clinical outcomes, prevalence difference cases vs comparators
- prevalence difference (infections) +17.3%; P < 0.001
- Clinical outcomes, prevalence difference cases vs comparators
- prevalence difference (hypertension) +15.5%; P < 0.01
- Clinical outcomes, prevalence difference cases vs comparators
- prevalence difference (diabetes mellitus) +15.0%; P < 0.001
- Increased from +8.8%
- prevalence difference (malignancy, end of follow-up) +12.5%; P < 0.001
Observational data: associations, not effects.
Further findings
Hospitalization · over follow-up
P < 0.01
ED visit · over follow-up
P < 0.01
- GC use in cases
- 64.0%
- Pancreatic enzyme replacement therapy use in cases · during follow-up
- 17.4%
- GC use in cases: 64.0% prior to index date
Healthcare costs · over follow-up
- All costs were greater in cases than comparators
Original publication
The clinical outcomes and healthcare resource utilization in IgG4-related disease: a claims-based analysis of commercially insured adults in the United States. Rheumatology (Oxford). Published 19 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →